Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck KGaA's Cladribine Revival Smacks Of Desperation

This article was originally published in Scrip

Executive Summary

In a surprise development, Merck KGaA has decided to file for approval of cladribine, the oral multiple sclerosis medicine it suspended in late-stage trials more than four years ago. It now says that, having evaluated new data and done additional analyses of the product's benefit-risk profile, it will file for approval in Europe in the first half of 2016, and that it is developing plans for filings in other markets.

You may also be interested in...



Merck KGaA Foresees Mid-2019 US Launch Of Oral MS Therapy Mavenclad

German Merck tells Scrip Mavenclad's long spell in the regulatory 'wilderness' allowed it to amass deep safety and efficacy data that should help the oral MS drug's commercial prospects.

Interview: German Merck Set For Big "Leap" In India

Germany's Merck Group appears set to build on its strong showing in India. Belén Garijo, CEO of Healthcare at Merck KGAA, tells Scrip about efforts to "consumerize" the firm's primary care business, how Erbitux is the "backbone" on which the company will build its oncology presence, and plans to roll out new products including the clinical stage immune-oncology asset avelumab, in India.

Merck KGaA Previews Cladribine Regulatory Revival Story At ECTRIMS

With the EMA’s review of the latest MAA for cladribine ongoing, Merck KGaA uses ECTRIMS 2016 to showcase longer-term efficacy data and a safety analysis that could lay to rest concerns about the multiple sclerosis therapy's risk of malignancy.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC029729

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel